Commentary

Podcast

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

Welcome to OncLive On Air®! I’m your host today, Chris Ryan.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Janssen, we had the pleasure of speaking with Saad Z. Usmani, MD, MBA, FACP, FASCO, about the FDA approval of ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid). Dr Usmani is a hematologist-oncologist and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.

On April 5, 2024, the regulatory agency approved the new indication for cilta-cel based on data from the phase 3 CARTITUDE-4 study (NCT04181827), which showed that at a median follow-up of 15.9 months (range, 0.1-27.3), patients treated with the CAR T-cell therapy (n = 208) experienced a median progression-free survival that was not yet reached compared with 11.8 months (95% CI, 9.7-13.8) for patients given standard-of-care combination regimens (n = 211; HR, 0.26; 95% CI, 0.18-0.38; P <.001).

In our exclusive interview, Dr Usmani detailed the significance of the approval of cilta-cel for the treatment of select patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy; expanded on the efficacy and safety data derived from CARTITUDE-4; and explained where the CAR T-cell therapy now fits in the multiple myeloma treatment paradigm.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Janssen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.

Related Videos
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer